First-line treatment of EGFR-mutated non-small cell lung cancer: concurrent Osimertinib plus Gefitinib
First-line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) is standard of care for patients with EGFR-mutated non-small-cell lung cancer ( NSCLC ).
The EGFR TKI Osimertinib ( Tagrisso ) is active against the acquired Gefitinib-resistant mutation EGFR T790M, as is Gefitinib ( Iressa ) against the Osimertinib-resistant EGFR C797S.
Preclinical evidence has suggested dual EGFR inhibition with Gefitinib + Osimertinib may delay emergence of acquired resistance.
A ongoing phase I/II study enrolled patients with stage IV EGFR-mutated ( L858R or del19 ) NSCLC, without prior therapy for metastatic disease.
Treatment in dose escalation ( n = 6 ) was: concurrent Osimertinib 40 mg or 80 mg + Gefitinib 250 mg daily.
In dose expansion ( n = 21 ), the combination of Osimertinib and Gefitinib was used at the maximum tolerated dose ( MTD ).
Prior to protocol amendment 6 patients received alternating monthly cycles of TKI monotherapy and were excluded from this analysis.
The primary endpoints in the dose escalation and expansion phases were, respectively, identification of the maximum tolerated dose and feasibility, defined as receipt of combination therapy for greater than or equal to 6 four-week cycles.
Secondary endpoints included overall response rate ( ORR ), survival outcomes, plasma EGFR mutation clearance ( cell free DNA by droplet digital PCR [ ddPCR ] ), and mechanisms of acquired resistance.
From May 2017 to July 2019 27 patients were enrolled and evaluable for the primary endpoints.
The maximum tolerated dose was Osimertinib 80 mg plus Gefitinib 250 mg orally daily.
In feasibility analysis, 81.5% completed greater than or equal to 6 cycles combination therapy ( 1 patient discontinued for progression, 4 for toxicity ).
The ORR was 85.2% ( 95% CI 67.5%-94.1% ). Best response was: 85.2% partial response ( PR ), 14.8% stable disease ( SD ).
The most common treatment-related adverse effects ( TRAEs ) ( % any grade, % grade 3 ) were rash ( 96.3%, 3.7% ), diarrhea ( 85.2%, 11.1% ) and dry skin ( 70.4%, 0% ).
Plasma ddPCR ( n = 25 pts ) detected the driver EGFR mutation at baseline in 68% of patients.
In these patients, plasma EGFR cleared to undetectable at 2 weeks treatment in 82.4%.
At 14.8 months median follow up the median progression free survival was not yet reached.
In conclusions, combination therapy with Osimertinib and Gefitinib is tolerable for first-line treatment of EGFR-mutated non-small cell lung cancer and resulted in rapid plasma clearance of the EGFR mutation.
The observed ORR is consistent with previously reported first-line response rates to Osimertinib.
Analysis of survival outcomes and acquired resistance mechanisms are pending data maturity and will facilitate understanding of the role of first-line dual EGFR TKI therapy for this population. ( Xagena )
Source: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020
Resected stage III melanoma with BRAF mutations: 5-year follow-up of adjuvant Dabrafenib plus Trametinib - Findings from the COMBI-AD study
Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...
Efficacy and safety of Pembrolizumab plus chemotherapy to Pembrolizumab monotherapy: a consecutive analysis of NSCLC patients with high PD-L1 expression
There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...
Primary Ipilimumab / Nivolumab immunotherapy followed by adjuvant Nivolumab in locally advanced or oligometastatic melanoma: preliminary results
The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...
ALEX study: updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer
The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...
The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...
Ayvakyt for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors, approved by European Commission
The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...
Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
The coronavirus disease 2019 ( COVID-19 ) virus, emerged in December 2019, has spread rapidly, with cases now confirmed in...